DISCLAIMER
This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

FORWARD-LOOKING STATEMENTS
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
COMPANY HIGHLIGHTS

- MADX: ORY  A publicly traded company in the Madrid Stock Exchange since December 14th 2015
- Trading started at €3.39 = €96.5M Market Cap
- A clinical stage biopharmaceutical company developing innovative therapies in oncology and neurodegeneration leading the field of Epigenetics
- Two therapeutic programs in clinical development with multiple indication opportunities & additional assets in preclinical development
- Signed global strategic partnership with ROCHE for ORY-1001 valued at 500M USD
- Strong IP portfolio with technology developed in-house
- Strong financial profile with €+20M cash on balance sheet with runway till 2018
- Experienced management team
**Epigenetics** – the study of heritable changes in genome function that occur without a change in DNA sequence

- These changes mainly occur due to variations in the structure of chromatin that silence or activate whole regions of the chromosome and all the genes that reside in this region
- These variations are caused by post-translational modifications on histones, the proteins that serve as scaffold for the DNA to conform the chromatin
- Lysine methylation and demethylation is one of the key epigenetic modifications of the Histone tails
EPIGENETICS COMPETITIVE LANDSCAPE

EPIGENETICS is a new Space being explored by the Pharma Industry: Clinical Programs are still in Early Phases.

ORYZON, Epizyme and Constellation are the only Biotechs developing more than one compound.

GSK, Roche, Merck, Pfizer, Celgene and other Big Pharmas are also entering in the field either through their own programs or through alliances.

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>COMPOUND</th>
<th>DESCRIPTION</th>
<th>INDICATION</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reverlogix</td>
<td>RVX-208</td>
<td>BET bromodomain inhibitor</td>
<td>Atherosclerosis - Diabetes</td>
<td>Phase II b</td>
</tr>
<tr>
<td>Acetylon Pharmaceuticals</td>
<td>(ACY-1215) lic. to Celgene</td>
<td>Oral selective HDAC6 inhibitor</td>
<td>Multiple myeloma (MM)</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>Oryzon Genomics</td>
<td>ORY-1001 lic. to Roche</td>
<td>Lysine-specific demethylase 1 (LSD1) inhibitor</td>
<td>Acute myelogenous leukemia (AML)</td>
<td>Phase I/IIa</td>
</tr>
<tr>
<td></td>
<td>ORY-2001</td>
<td>LSD1-MAOB dual inhibitor</td>
<td>Alzheimer's Disease</td>
<td>CTA filed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other Neurodegenerative disorders</td>
<td></td>
</tr>
<tr>
<td>Constellation Pharmaceuticals</td>
<td>CPI-1205</td>
<td>EZH2 inhibitor</td>
<td>lymphoma</td>
<td>Phase II</td>
</tr>
<tr>
<td></td>
<td>CPI-0610</td>
<td>BET bromodomain inhibitor</td>
<td>Progressive Lymphoma AL, MDS, myeloproliferative neoplasms Multiple myeloma</td>
<td>Phase I</td>
</tr>
<tr>
<td>Epizyme</td>
<td>EPZ 6438 Tazemetostat</td>
<td>EZH2 inhibitor</td>
<td>non-Hodgkin B-cell lymphoma Synovial Sarcoma</td>
<td>Phase I/II IND / Phase I</td>
</tr>
<tr>
<td></td>
<td>EPZ-5676 lic. to Celgene</td>
<td>HMT DOT1L inhibitor</td>
<td>MLL- AML</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>Tensha Therapeutics</td>
<td>TEN-010</td>
<td>BET bromodomain inhibitor</td>
<td>Cancers including NUT midline carcinomas</td>
<td>Phase I</td>
</tr>
</tbody>
</table>
# Extensive Pipeline with Multiple Indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target</th>
<th>Molecule</th>
<th>Discovery</th>
<th>H2L</th>
<th>Lead Optimization</th>
<th>Preclinical</th>
<th>Phase I-IIa</th>
<th>Phase IIb</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>Leukemia</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid Tumors</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dementias</strong></td>
<td>LSD-1-MAOB</td>
<td>ORY-2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Disease</td>
<td>LSD-1-MAOB</td>
<td>ORY-2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s Disease</td>
<td>LSD-1-MAOB</td>
<td>ORY-2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Dementias</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Orphan</strong></td>
<td>LSD-1-MAOB</td>
<td>ORY-2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huntington’s Disease</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Orphan Diseases</td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Indications</strong></td>
<td>LSD-1</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>Other KDMs</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td>Other Epigenetic Targets</td>
<td>ORY-1001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
LSD1 PROGRAM: AN EPIGENETIC “ERASER”

✓ Lysine-specific histone demethylase 1 (LSD1 or KDM1A) is an enzyme that demethylates histones (removes methyl groups), specifically mono and di-methylated H3K4 and H3K9

✓ LSD1 belongs to the family of flavin adenine dinucleotide, dependent amine oxidases, which include known drug targets such as MAO-A and MAO-B

✓ LSD1 is located in the nucleus, unlike MAOs

✓ LSD1 expression has a high correlation in many solid tumors

✓ In some aggressive Leukemia, Leukemia Stem Cells are addicted to LSD1 activity

✓ The pan-MAO inhibitor tranylcypromine: a chemical starting point to design covalent LSD1 inhibitors.

✓ Protected by 19 patent families filed globally with 10 granted in US
ORYZON’s CLINICAL ONCOLOGY PROGRAM: **ORY-1001**

- KDM1A is a key effector of the differentiation block in MLL leukemia
- KDM1A sustains expression of the MLL-AF9 oncogenic program
- Nanomolar KDM1A inhibitor concentrations induce differentiation of human AML cells
- KDM1A inhibition in vivo targets MLL-AF9 cells, but spares normal repopulating cells.

Oryzon’s LSD1 inhibitor (OG-86) blocks progression of leukemia cells into the circulation MLL-AF9 mice model

Oryzon’s LSD1 inhibitor (OG-86) targets leukemia stem cells but spares normal hematopoietic stem cells

Modified from Harris et al., Cancer Cell. 2012: 21(4):473-87)
ORY-1001: ONCOLOGY PROGRAM

- ORY-1001 a highly potent and selective LSD1 inhibitor with orphan drug status granted by the European Medicines Agency (EMA)

- Pharmacological Properties
  - High druggability
  - Optimal ADMET and PK profiles
  - Orally bioavailable once daily
  - Easy to scale up
  - Good pharmaceutical properties

- Currently in Phase I/IIA
  - Completed Part 1 of the study (Phase I) in acute leukemia
  - Extension Arm (Phase II-A) ongoing

- Potential for additional indications, such as solid tumors (like SCLC) and sickle cell disease

- Global strategic collaboration with ROCHE valued >500M USD
In April 2014, Oryzon and ROCHE entered into a global collaboration to research, develop and commercialize LSD1 inhibitors, including ORY-1001, for oncology, hematology and non-malignant conditions.

Licensed compounds are covered by 2 patents in the Oryzon IP portfolio.

Remaining LSD1 inhibitors in Oryzon’s LSD1 IP portfolio are not part of the ROCHE license agreement.

Clinical development and all related investments beyond the ongoing Phase I/IIA trial are the responsibility of ROCHE.

Parties will collaborate on R&D through the ROCHE Translation Clinical Research Center (TCRC).

- Development and sales milestones total >500M USD
- Payment at contract signing plus near term milestone total 21M USD
- Sales royalty rates tiered up to mid-teens.
### PHASE I HIGHLIGHTS: ORY-1001 LEUKEMIA

<table>
<thead>
<tr>
<th><strong>TRIAL DESIGN</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory &amp; Relapsed Acute Leukemia</td>
<td>Multi-Center (5)</td>
</tr>
</tbody>
</table>

#### PRIMARY ENDPOINT
Evaluate Safety (hematological and non-hematological toxicities) and Tolerability

#### SECONDARY ENDPOINTS
- Characterize PK
- Assess Responses (CR/Cri/PR), particularly for rMLL gene
- Evaluate surrogate PD markers for target engagement

#### PRELIMINARY RESULTS
- Excellent safety profile with no SAEs
- Demonstrated impact on pharmaceutical target
- PD clear readings several biomarkers
- Good PK
- Established maximum recommended dose
PHASE IIA: ORY-1001 LEUKEMIA

After the MRD, an Expansion arm (Phase II-A) to include patients with target mutations (MLL and others) to evaluate preliminary signs of efficacy.

9 Patients to be included
Status: 3 patients enrolled and actively recruiting
Completion Date: 2Q-2016

10 Hospitals in 3 Countries

→ UK
  • Christie Hospital, Manchester
  • University College London hospitals NHS, London

→ FRANCE
  • Gustave Roussy, Paris
  • CHU Hopitaux, Bordeaux
  • Hôpital Purpan - (CHU), Toulouse

→ SPAIN
  • Valle de Hebron, Barcelona
  • La Fe, Valencia
  • Virgen del Rocío, Sevilla
  • 12 de Octubre, Madrid
  • Gregorio Marañoñ, Madrid
ORY-1001 CLINICAL & MARKET POTENTIAL

ORY-1001 market capture opportunity above $1.8 billion.

A number of scientific reports point out the potential of LSD1 inhibition as a target in a number of solid tumors.

Non oncological diseases as SCD and others may also be a CDP option.

### Acute Myeloid Leukemia
- 12% of all Blood Cancers
- 18,860 new cases in US in 2014
- Global Mk Potential of $932 million in 2024, CAGR of 10.5%

### Small Cell Lung Cancer
- 15% of all Lung Cancers
- 32,420 new cases in US in 2014
- Global Mk Potential of $684 million in 2017

### Sickle Cell Disease
- SCD Epidemiology
- US/EU Prevalence ~150K
- US Mk Potential of $200 million in 2017,
  (Market to grow at 17% CGAR till 2019)

**NOTE:** ROCHE is the sole responsible for the further clinic development Plan for ORY-1001. The indications and markets mentioned above are only presented on its likelihood based on the development of competitors or published scientific reports.

1. ACS, Cancer Facts & Figures 2014
2. [www.hematology.org](http://www.hematology.org)
3. [www.lungcancer.org](http://www.lungcancer.org)
4. Global Data 2015
5. Decision Resources 2015
Studies suggest epigenetic modifications that induce alterations in gene expression programs contribute to neurodegenerative disorders:

- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Huntington’s Disease (HD)

Epigenetic alterations on related genes may also result in neurodegeneration, partially accounting for the etiology.

Epigenetic drugs target the proteins responsible for modifications on DNA or histone:

- HDAC inhibitors (HDACi)
- HAT modulators
- DNA methyltransferase inhibitors
- Histone demethylase inhibitors

Identical twins (monozygotic)
- Same DNA with GBA risk mutation
- Disconcordant for symptoms of Parkinson’s
- Up to 20 years difference in onset
- Patient derived iPSCs: difference in MAO-B levels
HDACi improves HD symptoms in animal models

HDAC2 inhibition recovers memory on the bi-transgenic CK-p25 Tg mouse model

HDAC inhibition improves FTD

Efforts to develop Selective HDACi

HDAC2 selective inhibitors in AD

HDAC i in Prodromal to Moderate FTD with Granulin Mutation

However, while pan-HDAC inhibitors have demonstrated preclinical proof of concept that inhibition of HDACs improves cognitive function, these drugs have dose limiting side effects that make them unsuitable for the chronic settings needed in neurological indications.

Developing more selective HDAC inhibitors is not an insignificant challenge as HDACs are highly conserved proteins.

Luca Lovrečić, et al., 2013 The Role of Epigenetics in Neurodegenerative Diseases
LSD1 is a key component of the LSD1-REST-CoREST-HDAC1/2 repressor complex involved mainly in controlling developmental programs and modulating neuronal morphology in the CNS.

LSD1 is known to be an important regulator in the maintenance of pluripotency and in specification of neuronal commitment of pluripotent or multipotent cells.

Different to what happens in HDACs, it has been proven that it is possible to develop extremely selective LSD1 inhibitors with excellent pharmacological properties.

Oryzon has the wider IP portfolio in the LSD1 space with drug candidates specially suitable to be developed in neurological indications.
ORY-2001 is a highly selective dual LSD1-MAO-B inhibitor
Preclinical Proof of Concept: LSD1 Against AD and HD

Clinical development
- CTA Filed
- Phase I to start in 1Q2016

Alzheimer’s Disease is lead indication
Potential for additional indications: PD, HD and others
Exclusively owned by Oryzon

Pharmacological Properties
- Optimal ADMET and PK profiles
- Crosses efficiently the BBB
- Once daily oral bioavailable
- Good pharmaceutical properties
- Selectivity against MAO-A demonstrated in-vitro and in-vivo
- High therapeutic window in animals
PoC studies in SAMP8 mice

✔ The SAMP8 mouse is an excellent model to examine the pathophysiology of early defects seen in Alzheimer’s disease. They develop accelerated aging and senescence and show deficits in learning and memory as well as other similarities to pathology of AD

✔ ORY-2001 cognitive effect tested by NORT in five different studies

✔ After 2 and 4 month of oral treatment, ORY-2001 provides a robust protective effect in the medium and long-term memory of female mice, compared to age-matched SAMP8 mice

✔ We lowered dose in males (Study #2)
PoC studies in SAMP8 mice

Dissecting the LSD1 and MAOB components

- MAOB inhibition alone shows a trend on cognitive improvement on the SAMP8 animals but it is not significant
  - $p=0.12$ at 2h
  - $p=0.22$ at 24h

- LSD1 inhibition is therefore crucial to obtain the recovery on cognitive improvement on the SAMP8 animals

<table>
<thead>
<tr>
<th>SAMP8 male animals (n=8 per group)</th>
<th>LSD1+MAOB</th>
<th>LSD1 alone</th>
<th>MAOB alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 month treatment 2h retention test</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
</tbody>
</table>

**Diagram:**
- **SAMPR1**
- **Veh**
- **ORY-2001**
- **ORY-2001**
- **Rasag.**

- **SAMPR1**
- **Veh**
- **ORY-2001**
- **ORY-2001**
- **Rasag.**

Discrimination Index (DI)

- **SAMPR1**
- **Veh**
- **ORY-2001**
- **ORY-2001**
- **Rasag.**

- **SAMPR1**
- **Veh**
- **ORY-2001**
- **ORY-2001**
- **Rasag.**
PoC studies in SAMP8 mice

Dissecting the LSD1 and MAOB components

- ORY-2001 provides a robust protective effect in the medium and long-term memory of mice, compared to age-matched SAMP8 mice.

- LSD1 inhibition alone is also able to produce an effect but less pronounced.

- Protection is driven by the LSD1 inhibition and not by MAO-B, but the combination with MAO-B inhibition (i.e. a dual compound, ORY-2001) enhances the effect.

![Graph showing discrimination index (DI) for different treatments in SAMP8 female animals.](image)
ORY-2001 - PROOF OF CONCEPT IN SAMP8 MICE

BIOMARKERS: We have identified different biomarkers upon ORY-2001 treatment:

- ORY-2001 has a pleiotropic effect on the hippocampal gene expression pattern and increases memory associated genes and reduces levels of inflammatory genes.

- Down-regulation of the pro-inflammatory S100A9 protein by ORY-2001 is particularly interesting, since S100A9 is emerging as an important contributor to inflammation-related neurodegeneration. S100A9 was found to be increased in patients with AD, postoperative cognitive dysfunction (POCD) and traumatic brain injury (TBI). In addition, knockout or knockdown of S100A9 has been shown to be beneficial to memory in APP/PS1 and Tg2576 models of Alzheimer’s disease.
ORY-2001 DEVELOPMENT TIMELINE

<table>
<thead>
<tr>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>3Q2015</td>
<td>4Q2015</td>
<td>1Q2016</td>
</tr>
<tr>
<td>1Q2016</td>
<td>2Q2016</td>
<td>3Q2016</td>
</tr>
<tr>
<td>3Q2016</td>
<td>4Q2016</td>
<td>1Q2017</td>
</tr>
<tr>
<td>2Q2017</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- CMC / 4W Reg Tox
- IB / IMPD
- CTA
- Phase I (SAD)
- Phase I (MAD)
- 6M Reg Tox
- Additional Preclinical Work to Broaden CDP
- Phase II Dossier
- Phase II AD
- Phase II Additional Indications
ORY-2001 market capture opportunity above $3 billion.

Further development may include Neuro-inflammatory disorders

ALZHEIMER’S DISEASE
5.4 M people currently affected in US. By 2025 the number of patients will rise to 7.1 million in USA\(^1\)
8.7 million Europeans are also affected \(^2\) and in Asia another potential 10 to 12 million people are diagnosed or suspected to suffer AD.

**Drug market projected to reach US $9.5 billion by 2017** \(^6\)

PARKINSON’S DISEASE
Around 6.3 million people have the condition worldwide\(^3\)
It affects over 1 million people in the US, with nearly 60,000 people newly diagnosed every year. \(^4\)

**Drug market projected to reach US $2.6 billion in 2020 in the 7MM**

HUNTINGTON’S DISEASE
Worldwide prevalence of HD is 5–10 cases per 100,000 persons. There are around 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease \(^5\)
Up to 71,000 patients in Europe.

**Drug market projected to reach US$1.3 billion by 2020** \(^7\)

---

1. Alzheimer’s association [www.alz.org](http://www.alz.org)
7. [http://www.strategyr.com](http://www.strategyr.com)
EXPERIENCED LEADERSHIP TEAM

☑️ Respected team in the European biopharmaceutical industry
☑️ Experienced in drug discovery and development. Able to bring assets to clinical stages in a cost efficient manner
☑️ Proven track record to promote and close world class deals
☑️ Ability to lead and unite teams. Leading international consortia

CARLOS BUESA
CEO and FOUNDER

TAMARA MAES
CSO and FOUNDER

ENRIC RELLO
COO and CFO-Spain

NEUS VIRGILI
CIPO

EMILI TORRELL
CBO

CESAR MOLINERO
CMO

ANNA BARAN
IR Director
FINANCIAL HIGHLIGHTS

- Strong balance sheet with €+20m in cash
- $5 million payment from ROCHE in 2015
- Secured €2.6M in public aids in 2015
- Unused credit line of €6 M from commercial banks
- €10M in debt with low interest rates
  - Repayment terms over either 3-4y or 8-10y (commercial loans or Public R&D loans)
  - Rates from 0-3% (average cost of debt 1,3%)
- Expected cash burn of €10-12M annually for next 2 years
- Raised €31 M since inception
- Spanish GAAP rules adapted to IFRS
- Accounts audited by Grant Thornton since 2003 and through 2014
- Audited in 1H 2015
- 35 employees
KEY INVESTMENT HIGHLIGHTS

**EPIGENETICS**
- Global leader in Epigenetics, an emerging field recognized by the pharmaceutical industry as a novel approach to varying diseases and personalized medicine

**EXTENSIVE PIPELINE**
- 2 programs in clinical development
- Both clinic programs can expand in multiple indications
- An Epigenetic platform with additional assets

**PROVEN TRACK**
- Collaborative agreement with ROCHE valued at $500 million
- Cutting edge science endorsed by international agencies

**SOLID IP**
- Strong patent portfolio with 19 patent families and 10 granted in US
- All patented technology developed in-house with no owed royalties

**LEADERSHIP**
- Highly experienced management team

**FINANCIALS**
- €+20M on balance sheet with runway till 2018
- Plan to grow as a public company in Europe and dual list on NASDAQ in the future
ORY-1001: LEAD CANCER ASSET
- Conclude Phase I dosing study
- Receive recommended dose milestone payment from Roche
- Phase IIA first patient-in
  - Complete Phase IIA and report target efficacy
  - Roche execute ongoing clinical development plan

ORY-2001: LEAD CNS ASSET
- Complete preclinical toxicology package
- File CTA/IND
  - Begin Phase I patient enrolment
  - Complete Phase I dosing safety study
  - Layout of a multiple Phase II clinical study

CORPORATE
- €16.5M cross over funding in Spain
- List on the Spanish Main Market
  - Prepare to List on the NASDAQ in the future
Our research has been partly funded by competitive grants
ORYZON IS A TRANSATLANTIC COMPANY

UNITED STATES
ORYZON Corp.
245 First Street
Suite 1800
Cambridge, MA 02142

⇒ Investor Relations
⇒ US Clinical Operations
⇒ Business Development

EUROPE
ORYZON
Sant Ferran, 74
08940 Cornellà de LL.
Barcelona, Spain

⇒ Research and Development
⇒ European Clinical Trials
⇒ Intellectual Property
THANK YOU VERY MUCH!

CARLOS BUESA
C.E.O. & President
cbuesa@oryzon.com

ANNA K. BARAN
IR Director
abarans@oryzon.com

EMILI TORRELL
BDO
etorrell@oryzon.com

THE RUTH GROUP
IR firm for USA
oryzon@theruthgroup.com